Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Active, not recruiting · Phase 2 · NCT05479994
Conditions: Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia
At a glance
- Research payments reported, 2025
- $27,820
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- BeiGene
- Tested
- BGB-11417 (drug)
- Dates
- Started 2022-10-25; completion 2027-08-25
- Results posted
- Not yet
The purpose of this study is to evaluate the efficacy of BGB-11417 in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
From ClinicalTrials.gov, last updated 2026-03-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $27,820 in research payments for this study in 2025 (23 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Peritus Imaging Inc $10,290
- $9,130
- Mgpo Radiology Associates $8,400
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.